29 completed, 13 active not recruiting, 9 terminated, 8 withdrawn. 40 Phase 2, 16 Phase 1, 16 Phase 3, 1 Early Phase 1.
Follow elotuzumab: new trials by email Literature Review of elotuzumab trials Research Report on elotuzumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Inobrodib, Pomalidomide and Dexamethasone Versus Standard Available Therapy in Relapsed or Refractory Multiple Myeloma InoPd, Investigator's choice of SAT - Multiple Myeloma Refractory, Multiple Myeloma in Relapse | Phase 3 | Recruiting | CellCentric Ltd. | 450 | 2026-08-01 | 2026-08-19 |
| Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma Cevostamab, Pomalidomide, Dexamethasone - Multiple Myeloma | Phase 3 | Recruiting | Hoffmann-La Roche | 380 | 2026-06-23 | 2026-10-13 |
| Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan - Recurrent Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 37 | 2025-03-18 | 2026-06-25 |
| Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM Elotuzumab, Iberdomide, Dexamethasone - Myeloma, Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | Omar Nadeem, MD | 49 | 2024-11-01 | 2026-10-07 |
| Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma Etentamig, Carfilzomib, Pomalidomide - Multiple Myeloma | Phase 3 | Active not recruiting | AbbVie | 421 | 2024-05-19 | 2026-08-27 |
| A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) Alnuctamab, Pomalidomide, Daratumumab - Multiple Myeloma | Phase 3 | Withdrawn | Celgene | 2024-05-03 | 2024-05-31 | |
| MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) Elranatamab, Elotuzumab, Pomalidomide - Multiple Myeloma | Phase 3 | Recruiting | Pfizer | 492 | 2024-02-08 | 2026-08-24 |
| A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide Talquetamab, Pomalidomide, Teclistamab - Multiple Myeloma | Phase 3 | Active not recruiting | Janssen Research & Development, LLC | 838 | 2024-01-22 | 2026-09-25 |
| A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan Elotuzumab in combination with pomalidomide and dexamethasone, Elotuzumab in combination with lenalidomide and dexamethasone - Relapsed or Refractory Multiple Myeloma | Completed | Bristol-Myers Squibb | 7 | 2023-12-22 | 2025-07-31 | |
| Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Active not recruiting | Abdullah Khan | 12 | 2023-12-21 | 2026-05-13 |
| A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma Linvoseltamab, Elotuzumab, Pomalidomide - Relapsed Refractory Multiple Myeloma (RRMM) | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 410 | 2023-09-18 | 2026-10-07 |
| Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy Allogeneic Stem Cells, carfilzomib/lenalidomide/dexamethasone (KRD), elotuzumab/lenalidomide/dexamethasone (ERD) - Multiple Myeloma | Phase 3 | Terminated | Universitätsklinikum Hamburg-Eppendorf | 28 | 2023-03-03 | 2026-01-05 |
| A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma Iberdomide, Elotuzumab, Dexamethasone - Multiple Myeloma | Early Phase 1 | Active not recruiting | Icahn School of Medicine at Mount Sinai | 7 | 2023-02-06 | 2026-01-02 |
| Elotuzumab, Selinexor, and Dexamethasone for Relapsed Refractory Multiple Myeloma Elotuzumab, Selinexor, and Dexamethasone (ESd) - Relapsed Multiple Myeloma, Refractory Multiple Myeloma | Phase 2 | Withdrawn | Tulane University School of Medicine | 2022-04-27 | 2022-05-04 | |
| A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma Selinexor, Elotuzumab, Pomalidomide - Multiple Myeloma | Phase 3 | Active not recruiting | European Myeloma Network B.V. | 117 | 2022-04-19 | 2025-12-04 |
| Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma Elotuzumab, Belantamab mafodotin - Multiple Myeloma | Phase 1 / Phase 2 | Active not recruiting | Yale University | 24 | 2022-02-21 | 2026-05-13 |
| Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma Isatuximab (for run-in portion), Isatuximab (for expansion), Pomalidomide - Multiple Myeloma | Phase 2 | Active not recruiting | Medical College of Wisconsin | 28 | 2022-01-10 | 2026-03-27 |
| Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD) elotuzumab, placebo for elotuzumab, methylprednisolone - IgG4 Related Disease, IgG4-RD | Phase 2 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 8 | 2021-10-13 | 2026-02-05 |
| Phase II Study of Immunomaintenance Using POmalidomide With Elotuzumab afteR Second Autologous Transplant Elotuzumab, Pomalidomide - Multiple Myeloma | Phase 2 | Withdrawn | Natalie Callendar | 2021-04-01 | 2021-08-23 | |
| Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis Elotuzumab, Questionnaire Administration - Myelofibrosis Transformation in Essential Thrombocythemia, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 15 | 2021-02-10 | 2026-06-11 |
Showing 20 of 71. Sign in to see all of them.
Multiple Myeloma (60) · Recurrence (11) · Neoplasms, Plasma Cell (3) · Hematologic Neoplasms (2) · Smoldering Multiple Myeloma (2) · Immunoglobulin G4-Related Disease (1) · Immunoglobulin Light-chain Amyloidosis (1) · Leukemia, Myeloid, Acute (1) · Leukemia, Plasma Cell (1) · Lymphoma (1) · Neoplasms (1) · Polycythemia Vera (1) · Primary Myelofibrosis (1)
Bristol-Myers Squibb (19) · Celgene (3) · Dana-Farber Cancer Institute (3) · M.D. Anderson Cancer Center (3) · University of Arkansas (3) · Mayo Clinic (2) · AbbVie (1) · AbbVie (prior sponsor, Abbott) (1) · Abbott (1) · Abdullah Khan (1) · Assistance Publique - Hôpitaux de Paris (1) · Barbara Ann Karmanos Cancer Institute (1) · CellCentric Ltd. (1) · European Myeloma Network B.V. (1) · Facet Biotech (1)
United States (53) · Spain (18) · Canada (16) · Germany (16) · Italy (15) · France (13) · Greece (13) · Japan (13) · Australia (10) · United Kingdom (10) · Belgium (9) · Czechia (9) · Poland (9) · Israel (8) · Austria (7)
Abdullah M Khan, MBBS, MSc (1) · Andrew J Yee, MD (1) · Andrzej Jakubowiak, MD (1) · Anil Singhal, PhD (1) · Ann Mohrbacher, M.D. (1) · Binod Dhakal, MD (1) · Cesar Rodriguez, MD (1) · Faith Davies, MD (1) · Faith E Davies, MD (1)
PMID 23927993, PMID 26035255, PMID 26686406, PMID 27091875, PMID 27848182, PMID 28070715, PMID 28148715, PMID 30204239, PMID 30352784, PMID 30403938, PMID 31138244, PMID 31433920, PMID 32398792, PMID 33357482, PMID 33461512, PMID 34818965, PMID 35027656, PMID 35550060, PMID 35862034, PMID 35960908, PMID 36762851, PMID 37127471, PMID 37393120, PMID 37990162, PMID 38194610, PMID 38302221, PMID 38609316, PMID 38651976, PMID 38652812, PMID 38826786, PMID 39187595, PMID 39197072, PMID 39321347, PMID 39626297, PMID 39865222, PMID 41627370
2023 (4), 2016 (2), 2017 (2), 2014 (1), 2015 (1), 2018 (1), 2025 (1), P30CA022453 (1), U10CA032102 (1), U10CA180888 (1), UM1AI144298 (1)